{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T15:57:33Z","timestamp":1788623853196,"version":"build-2803163510"},"reference-count":9,"publisher":"Oceanside Publications Inc.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> During the height of the SARS CoV-2 (severe acutre respiratory syndrome coronavirus disease 2019 [COVID 19]) pandemic, there have been numerous case reports of cutaneous reactions shortly after COVID-19 vaccine administration. Most reported cases are local injection-site\n reactions, whereas persistent or delayed cutaneous reactions have not been as common.  <jats:bold>Methods:<\/jats:bold> We present the case of an 82-year-old man with persistent rash after the second COVID-19 vaccination.  <jats:bold>Results:<\/jats:bold> A specific diagnosis was confirmed after the\n third skin biopsy.  <jats:bold>Conclusion:<\/jats:bold> Patients are frequently referred to an allergist for various cutaneous reactions that occurred after vaccination, concerned about a possible drug allergy. This case emphasizes the importance of keeping a broad differential diagnosis when encountering\n a persistent skin rash not resolved by oral antihistamines or steroids.<\/jats:p>","DOI":"10.2500\/aap.2024.45.230062","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:39:42Z","timestamp":1703738382000},"page":"70-73","source":"Crossref","is-referenced-by-count":11,"title":["An 82-year-old man with new skin lesions after COVID-19 vaccination"],"prefix":"10.2500","volume":"45","author":[{"given":"Patricia J.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merritt L.","family":"Fajt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.det.2021.05.016","article-title":"COVID-19 vaccines and the skin: the landscape of cutaneous vaccine reactions worldwide","volume":"39","author":"Sun","year":"2021","journal-title":"Dermatol Clin"},{"key":"B2","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2002-07-1960","article-title":"Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients","volume":"102","author":"Bekkenk","year":"2003","journal-title":"Blood"},{"key":"B3","first-page":"1361","article-title":"Peripheral T-cell lymphomas of the intestine","volume":"141","author":"Chott","year":"1992","journal-title":"Am J Pathol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","article-title":"Racial patterns of peripheral t-cell lymphoma incidence and survival in the United States","volume":"34","author":"Adams","year":"2016","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2021.03.092","article-title":"Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases","volume":"85","author":"McMahon","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1111\/jdv.17736","article-title":"Recurrence of cutaneous T-cell lymphoma post viral vector COVID-19 vaccination","volume":"36","author":"Panou","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1080\/10428194.2021.1924371","article-title":"Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination","volume":"62","author":"Brumfiel","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2024\/00000045\/00000001\/art00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T04:41:14Z","timestamp":1703738474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2024.45.230062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"alternative-id":["1088-5412(20240101)45:1L.70;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2024.45.230062","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,1]]}}}